

VIRTUAL
FORMAT

12
•
13
Feb
2026

Innovation in Breast Cancer

iBC 2026

DIRECTORS

Francisco Ayala

*Hospital General Universitario
Gregorio Marañón, Madrid, Spain*

Miguel Martín

*Hospital General Universitario
Gregorio Marañón, Madrid, Spain*

16:30-16:40 **Introduction**
Miguel Martín
Hospital General Universitario Gregorio Marañón, Madrid, Spain
Francisco Ayala
Hospital General Universitario Gregorio Marañón, Madrid, Spain

16:40- 18:20 **Session 1: General Topics**

Chair Francisco Ayala
Hospital General Universitario Gregorio Marañón, Madrid, Spain

16:40-17:00 **Beyond five years: clinical and genomic predictors of late recurrence in HR+/HER2- early breast cancer**
Michael Gnant
Comprehensive Cancer Center, Medical University of Vienna, Austria

17:00-17:10 **Discussion**

17:10-17:30 **Should nodal irradiation replace axillary surgery?**
Philip Poortmans
University of Antwerp, Belgium

17:30-17:50 **AI-based histopathology as a prognostic tool in early breast cancer**
Calvin Chao
ArteraAI, California, USA

17:50-18:10 **Special situations in breast cancer**
Francisco Ayala
Hospital General Universitario Gregorio Marañón, Madrid, Spain

18:10-18:20 **Discussion**

18:20-18:30 **Break**

18:30-20:00 **Session 2: Therapy 1**

Chair Luis Costa
Hospital de Santa Maria, Lisbon, Portugal

18:30-19:00 **Maximising patient benefit from adjuvant CDK4/6 inhibitors**
Michael Untch
Helios Hospital Berlin-Buch, Germany

19:00-19:20 **Identification of lower-risk triple negative subsets for therapy de-escalation**
Maria Vittoria Dieci
Professor at University of Padua, Italy

19:20-19:40 **A differential adjuvant strategy for early lobular breast cancer?**
Sherry Shen
Memorial Sloan Kettering Cancer Center, New York, USA

19:40-20:00 **Discussion**

16:30-17:50 **Session 3: General topics 2**

Chair: Carlos Barrios
Latin American Cooperative Oncology Group, Porto Alegre, Brazil

16:30-16:50 **ctDNA monitoring of residual disease to guide adjuvant therapy in early breast cancer**

Isaac García-Murillas
The Institute of Cancer Research, London, UK

16:50-17:10 **Guiding therapy with blood based biomarkers in advanced breast cancer**

Ángel Guerrero
Instituto Valenciano de Oncología, Spain

17:10-17:30 **Immune-mediated resistance to CDK4/6 inhibitors**

Giulia Petroni
Department of Experimental and Clinical Medicine,
University of Florence, Italy

17:30-17:50 **Discussion**

17:50-18:00 **Break**

18:00-19:20 **Session 4: Therapy 2**

Chair: Sara López-Tarruella
Hospital General Universitario Gregorio Marañón, Madrid, Spain

18:00-18:20 **Therapeutic approach after resistance to CDK4/6 inhibition**

Miguel Martín
Hospital General Universitario Gregorio Marañón, Madrid, Spain

18:20-18:40 **Antibody-drug conjugates for triple negative advanced breast cancer**

Sara M. Tolaney
Dana Farber Cancer Institute, Boston, USA

18:40-19:00 **Maintenance strategies in HER2-positive advanced breast cancer**

Véronique Diéras
Centre Eugène Marquis, Rennes, France

19:00-19:20 **Discussion**

19:20-19:30 **Closing remarks**

SPONSORS

GOLD



SILVER



BRONZE



OTHER COLLABORATIONS



WITH THE SCIENTIFIC ENDORSEMENT OF

GEicam
investigación en
cáncer de mama

SEOM
Sociedad Española
de Oncología Médica

SEOM® es una marca registrada.
El aval de SEOM no implica la
organización ni financiación del evento

ORGANIZED BY



FUNDACIÓN
KRONOS
Investigación Clínica Oncológica

HEALTH
COMMUNICATION

**DOCTA
FORUM**

Scientific Secretariat

Tel.: (+34) 670957548

e-mail: ibc@doctafortum.com

www.innovationinbreastcancer.com